Local Anesthesia Pain: A Predictor of Post-Cesarean Pain? Pain during infiltration of local anesthesia is linked to a higher intensity of pain 24 hours after cesarean delivery and lower global health ...

New Pulsed-Field Ablation Device Found Effective at 1 Year On the heels of the first pulsed-field ablation device to win approval for atrial fibrillation ablation, a novel version of the technology ...

Medscape UK -- with comprehensive coverage of the NHS, UK & NICE guidelines, drugs alerts, and the latest medical research of interest to doctors in England, Scotland, Wales, and Northern Ireland.

Clinicians caution that while the app flags possible anemia, definitive diagnosis requires lab testing, patient history and ...

Kennedy Replaces Fired US CDC Panel Members, Includes Anti-vaccine Proponents U.S. Health Secretary Robert Kennedy Jr. named eight members to serve on a key panel of vaccine advisers on Wednesday, ...

Can Dose Spacing of IL-17i Maintain Efficacy in Psoriasis? IL-17 inhibitors secukinumab and brodalumab demonstrate similar efficacy in patients with psoriasis for up to a year after dose spacing, ...

Psoriatic Arthritis From the Dermatologist’s Perspective Drs Tina Bhutani, Mona Shahriari, and Jason Hawkes explore how dermatologists are uniquely positioned to identify and manage psoriatic ...

Future Shock: Preventing Sudden Cardiac Death Is Possible Coronary artery disease and heart failure can raise the risk for sudden cardiac arrest, but implantable and wearable devices are literally ...

Psoriatic Arthritis From the Dermatologist’s Perspective Drs Tina Bhutani, Mona Shahriari, and Jason Hawkes explore how dermatologists are uniquely positioned to identify and manage psoriatic ...

Canada can build successful diabetes prevention and remission programs across the country by learning from England and ...

Acute dacryocystitis is common in women, and the risk for the condition rises with age, especially in those with primary acquired nasolacrimal duct obstruction.

ASCO 2025 Lymphoma: Dual-Targeting CAR T Shows Safety, Efficacy KITE-363, a dual-targeting CAR T-cell therapy, shows a strong safety profile and high responses in patients who have highly refractory ...